Loading stock data…
XGN
$3.06+0.16 (+5.52%)
Market ClosedLast close May 1
Exagen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Exagen Inc. in the Healthcare sector is trading at $3.06. The stock is currently near its 52-week low of $2.59, remaining 55.5% below its 200-day moving average. Technical signals show neutral RSI of 55 and bullish MACD crossover, explaining why XGN maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 55) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.06
Potential Upside
5%
Whystock Fair Value$3.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$64.94M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-97.31%
Volume
Today's trading volume
390,997
Recent News
Does Exagen (XGN)’s 200%+ Upside Potential Make It One of the Best Penny Stocks Set to Explode?
Exagen Inc. (NASDAQ:XGN) earns a spot on our list of the best penny stocks set to explode. As of April 8, 2026, analyst sentiment toward Exagen Inc. (NASDAQ:XGN) remains bullish, with over 80% of covering analysts maintaining ‘Buy’ ratings on the stock. The consensus price target of $10 implies a 235.01% upside. On March 11, […]
How Analyst Resets Are Reshaping The Exagen (XGN) Investment Story
Analysts have been trimming their price targets on Exagen, with recent updates clustering in the US$9 to US$10 range, while a fair value anchor of US$9.50 remains unchanged. These revisions are tied to softer pricing assumptions, more measured revenue curves, and a slower expected build in gross margins. At the same time, they still point to volume trends and long term earnings potential as key positives. As you read on, you will see how these moving pieces shape the evolving Exagen story and...
Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments
Exagen Inc (XGN) reports a near 20% revenue increase for 2025, driven by testing volume growth and strategic expansions, despite facing profitability challenges.
Exagen Q4 Earnings Call Highlights
Exagen (NASDAQ:XGN) executives said the company closed 2025 with record revenue and testing volume, pointing to progress from operational changes made over the past several years, while acknowledging near-term average selling price (ASP) pressure tied largely to a previously disclosed client billing
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
Exagen (XGN) delivered earnings and revenue surprises of 0.00% and +1.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?